Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models[1].
Hydroaurantiogliocladin is a quinol. Hydroaurantiogliocladin can be used as substrate for the quinol-cytochrome c oxidoreductase activity (beef heart enzyme)[1].
PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.
Pirozadil is a hypolipidemic agent.
L-Histidine-13C6,15N3 (H-His-OH-13C6,15N3) hydrochloride hydrate is the 13C- and 15N-labeled L-Histidine hydrochloride hydrate. L-Histidine hydrochloride hydrate (H-His-OH.HCl.H2O) is an endogenous metabolite.
YK11 is a partial agonist of androgen receptor, with osteogenic activity.
PTP1B-IN-8 is a potent and selective potent protein tyrosine phosphatase-1B (PTP1B) inhibitor extracted from patent CN103626692A, example 1[1].
Lafutidine-d10 is deuterium labeled Lafutidine. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease[1].
3,5-Dimethoxyphenol is a toxin metabolite, found in human consuming yew leaves[1].
T3 Acyl glucuronide, an endogenous metabolite, is the acyl glucuronide formation of triiodothyronine (T3)[1].
L-2-Aminooxy-3-phenylpropanoic acid hydrobromide is a potent inhibitor of L-phenylalanine ammonia-lyase[1].
2,6-Dihydroxyacetophenone is an endogenous metabolite.
Trimebutine-d5 is the deuterium labeled Trimebutine. Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects[1][2].
MB-07344 is a thyroid hormone receptor (TR)-β agonist with a binding affinity Ki of 2.17 nM[1].
PFKFB3-IN-2 is a 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor. PFKFB3-IN-2 has potential applications in cancer, neurodegenerative diseases, autoimmune diseases, inflammatory diseases, multiple sclerosis, metabolic diseases, angiogenesis inhibition and other diseases[1].
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent[1]. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability[1].
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent[1]. Tesofensine is a CNS acting anti-obesity agent[2].
Rp-8-Br-cGMPS (Rp-8-bromo-Cyclic GMPS) sodium salt is a potent Ca2+-ATPase activator. Rp-8-Br-cGMPS sodium salt mediates cytosolic Ca2+ reduction by activating Ca2+-ATPase and subsequently removing Ca2+ from the cell[1].
Phenylethanolamine A acts as a β-adrenergic agonist. Phenylethanolamine A is a byproduct during the Ractopamine synthesis process[1].
Cysteine Protease inhibitor is an inhibitor of cysteine protease. IC50 & Target: Cysteine Protease
Buformin (1-Butylbiguanide) is a potent and orally active biguanide antidiabetic agent, an AMPK activator. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].
GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect[1].
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1)[1].
β-Galactose dehydrogenase can make conversion of galactose to galactonolactone and the concomitant reduction of NAD to the fluorescent NADH. β-Galactose dehydrogenase can be used for the determination of galactose[1].
Caspase-3-IN-1 (compound 11b) is a potent Caspase-3 inhibitor, with an IC50 of 14.5 nM[1].
Xenin-8, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC50=0.16 nM)[1].
Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research[1][2].
m-Anisaldehyde-d3 is the deuterium labeled m-Anisaldehyde[1]. m-Anisaldehyde is an endogenous metabolite.
Bezeparsen is a PCSK9 synthesis inhibitor[1].
Camicinal (GSK962040) hydrochloride is a small molecule, selective motilin receptor agonist with pEC50 of 7.9.